Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-74.79%
0%
-74.79%
6 Months
-74.79%
0%
-74.79%
1 Year
-63.9%
0%
-63.9%
2 Years
-67.05%
0%
-67.05%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Herantis Pharma Oyj for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
6.43%
EBIT to Interest (avg)
-5.65
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.05
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
1.18%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
31.13
EV to EBIT
-10.07
EV to EBITDA
-10.07
EV to Capital Employed
-52.63
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-311.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
0.20
-8.00
102.50%
Interest
0.60
1.30
-53.85%
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.30
-9.30
103.23%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 103.23% vs 60.59% in Dec 2022
About Herantis Pharma Oyj 
Herantis Pharma Oyj
Pharmaceuticals & Biotechnology
Herantis Pharma Oyj is a Finland-based drug development Company with the purpose to evolve the treatment of diseases with unmet clinical needs, such as Parkinson’s disease and secondary lymphedema. The Company's product development portfolio includes: CDNF for Parkinson’s disease, Lymfactin in breast cancer-associated secondary lymphedema and Non-invasive xCDNF in neurodegenerative diseases.
Company Coordinates 
Company Details
Bertel Jungin aukio 1 , ESPOO None : 02600
Registrar Details






